

Special Issue

Long COVID: Pathophysiology, Symptoms, Treatment, and Management

Message from the Guest Editors

The symptoms of persistent coronavirus disease 2019 are increasingly well reported in the literature. These persistent symptoms following acute infection, also known as 'long COVID', have affected people worldwide. Long COVID is a heterogeneous disease with multimorbidities affecting several physiological systems. Given the pandemic's spread, the number of individuals suffering from long COVID is significant, currently estimated at over 100 million. Therefore, regularly collating high-quality research and innovative recovery solutions across various research areas is crucial. Our aim in launching this Special Issue is to consider long COVID pathophysiology, symptomology, treatment strategies, and management strategies, aiming to guide the process from benchtop to bedside. Additionally, articles within this Special Issue will explore the socioeconomic impact of long COVID, the role of rehabilitation programs, and the effectiveness of emerging therapeutic approaches. A multidisciplinary perspective is essential in understanding the full scope of long COVID, as it affects not only physical health but also mental well-being, quality of life, and workforce participation.

Guest Editors

Dr. Lawrence D. Hayes

Lancaster University Medical School, Lancaster University, Lancaster, UK

Dr. Nilihan E.M. Sanal-Hayes

School of Health and Society, University of Salford, Salford, UK

Deadline for manuscript submissions

31 January 2026



COVID

an Open Access Journal
by MDPI

Indexed in Scopus
Tracked for Impact Factor



mdpi.com/si/233256

COVID

MDPI, Grosspeteranlage 5

4052 Basel, Switzerland

Tel: +41 61 683 77 34

covid@mdpi.com

[mdpi.com/journal/
covid](https://mdpi.com/journal/covid)





COVID

an Open Access Journal
by MDPI

Indexed in Scopus
Tracked for Impact Factor



[mdpi.com/journal/
covid](https://mdpi.com/journal/covid)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Giuseppe Novelli

Department of Biomedicine & Prevention, Genetics Section, University
of Rome Tor Vergata, 00133 Rome, Italy

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid
by authors or their institutions.

High Visibility:

indexed within ESCI (Web of Science), Scopus, CAPIus /
SciFinder, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is
provided to authors approximately 20.3 days after
submission; acceptance to publication is undertaken in 2.8
days (median values for papers published in this journal in
the second half of 2024).